ORBi: Noël Agnès - Anti-angiogenic therapy of exudative age-related macular degeneration: current progress and emerging concepts

Reference : Anti-angiogenic therapy of exudative age-related macular degeneration: current progress ...


	Document type :	Scientific journals : Article
	Discipline(s) :	Human health sciences : Laboratory medicine & medical technology Life sciences : Biochemistry, biophysics & molecular biology
	To cite this reference:	http://hdl.handle.net/2268/3845

Title :	Anti-angiogenic therapy of exudative age-related macular degeneration: current progress and emerging concepts
Language :	English
Author, co-author :	Noël, Agnès [Université de Liège - ULg > Département des sciences biomédicales et précliniques > Biologie cellulaire et moléculaire appliquée à l'homme >]
	Jost, Maud [ > > ]
	Lambert, Vincent [Centre Hospitalier Universitaire de Liège - CHU > > Ophtalmologie >]
	Lecomte, Julie [Université de Liège - ULg > Département des sciences cliniques > Labo de biologie des tumeurs et du développement >]
	Rakic, Jean-Marie [Centre Hospitalier Universitaire de Liège - CHU > > Ophtalmologie >]
Publication date :	Aug-2007
Journal title :	Trends in Molecular Medicine
Publisher :	Elsevier Sci Ltd
Volume :	13
Issue/season :	8
Pages :	345-352
Audience :	International
ISSN :	1471-4914
City :	Oxford
Abstract :	[en] Age-related macular degeneration (AMD) is the leading cause of blindness in elderly patients. The more aggressive exudative form is characterized by abnormal blood-vessel development that occurs beneath the retina as a result of choroidal neovascularization (CNV). Vascular endothelial growth factor [VEGF) has emerged as the key mediator of CNV formation; this has led to intensive research on VEGF and the recent approval of anti-VEGF compounds by the US Food and Drug Administration. Despite this successful introduction of anti-angiogenic therapies into the clinical setting, there is still a lack of treatments that definitively reverse damaged vision. Here, we consider the importance of putative molecular targets other than VEGF that might have been underestimated. Emerging cellular mechanisms offer additional opportunities for innovative therapeutic approaches.
Permalink :	http://hdl.handle.net/2268/3845
DOI :	10.1016/j.molmed.2007.06.005
Other URL :	http://www.sciencedirect.com/science/journal/14714914

File(s) associated to this reference

Fulltext file(s):

	File	Commentary	Version	Size	Access
Open access	Noel trends 2007.pdf		Author postprint	324.55 kB	View/Open
Restricted access	Noel A trends2007.pdf		Publisher postprint	449.8 kB	Request copy

All documents in ORBi are protected by a user license.

Dspace v1.5